Investors who want to capitalize on the growing weight loss market might be tempted to turn to the current leaders in the field, Eli Lilly and Novo Nordisk. Both companies are worth serious consideration, in my view, but other drugmakers could also offer investors exposure to this area while having more diversified portfolios.
Some investors might be more attracted to this value proposition. That said, here are two companies quietly making progress in the weight-loss market that may be worth investing in today.
This post originally appeared at The Motley Fool.